Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Randi Y Leavitt

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 29, 2019
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantationFrancisco M Marty, Per T Ljungman, Roy F Chemaly, et al.
Current HIV Research|January 5, 2011
Long-term safety from the raltegravir clinical development programHedy Teppler, Deborah D Brown, Randi Y Leavitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionMartin S Hirsch, Roy T Steigbigel, Scholomo Staszewski, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2019
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell TransplantationPer Ljungman, Michael Schmitt, Francisco M Marty, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumBach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Open Forum Infectious Diseases|March 4, 2015
Safety Profile of the Merck Human Immunodeficiency Virus-1 Clade B gag DNA Plasmid Vaccine With and Without AdjuvantsErin K Quirk, Elizabeth L Brown, Randi Y Leavitt, et al.
AIDS (London, England)|April 28, 2011
Clinical efficacy of raltegravir against B and non-B subtype HIV-1 in phase III clinical studiesJürgen K Rockstroh, Hedy Teppler, Jing Zhao, et al.
Open Forum Infectious Diseases|May 9, 2017
Influence of Sex/Gender and Race on Responses to Raltegravir Combined With Tenofovir-Emtricitabine in Treatment-Naive Human Immunodeficiency Virus-1 Infected Patients: Pooled Analyses of the STARTMRK and QDMRK StudiesKathleen Squires, Linda-Gail Bekker, Christine Katlama, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 29, 2019
Outcomes of patients with detectable CMV DNA at randomization in the phase III trial of letermovir for the prevention of CMV infection in allogeneic hematopoietic cell transplantationFrancisco M Marty, Per T Ljungman, Roy F Chemaly, et al.
Current HIV Research|January 5, 2011
Long-term safety from the raltegravir clinical development programHedy Teppler, Deborah D Brown, Randi Y Leavitt, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 3, 2003
Long-term efficacy, safety, and tolerability of indinavir-based therapy in protease inhibitor-naive adults with advanced HIV infectionMartin S Hirsch, Roy T Steigbigel, Scholomo Staszewski, et al.
Clinical and Vaccine Immunology : CVI|July 17, 2009
Safety and immunogenicity of the Merck adenovirus serotype 5 (MRKAd5) and MRKAd6 human immunodeficiency virus type 1 trigene vaccines alone and in combination in healthy adultsClayton Harro, Xiao Sun, Jon E Stek, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 11, 2019
A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell TransplantationPer Ljungman, Michael Schmitt, Francisco M Marty, et al.
AIDS Research and Human Retroviruses|December 26, 2008
Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adultsClayton D Harro, Michael N Robertson, Michelle A Lally, et al.
Annals of the New York Academy of Sciences|March 26, 2011
Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentariumBach-Yen T Nguyen, Robin D Isaacs, Hedy Teppler, et al.
Pageof 2